Income Statement Presentation 2023

Roche ElecsysⓇ Amyloid Plasma Panel clinical results Received FDA approval for Elecsys Ⓡ CSF AD assays pTau/Abeta 42 1 Triage Patients undergoing initial evaluation for non-specific cognitive decline1 Elecsys Amyloid Plasma Panel² pTau 181+APOE4 sensitivity>85% specificity > 65% FDA BDD 2 Confirmation Patients referred for amyloid confirmatory testing³ Elecsys CSF AD assays pTau/Abeta 42 sensitivity >90% specificity >90% FDA 3 Therapy Patients identified for future therapies Anti-amyloid antibodies AD patients 吧吧吧 EOE 吧吧吧 Eo ° O 2 3 H = 10 patients 1 Assumed prevalence of AD 30% in symptomatic patients; 2 Mean of clinical performance data from retrospective cohorts measured with Elecsys Amyloid Plasma Panel; Blennow K et al. Clinical performance and robustness of blood-based biomarkers for early detection of amyloid pathology associated with Alzheimer's disease. Alzheimer's Dement. 2022, 18(6):e069052 ³ Alternative to PET scan 45 Non-AD patients

View entire presentation